Capital Research Global Investors Has $831.65 Million Stock Holdings in Cencora, Inc. $COR

Key Points

• Capital Research Global Investors increased its stake in Cencora by 0.6% in Q3 to 2,661,033 shares, representing about $831.65 million or roughly 1.37% of the company.
• Insiders have been net sellers: two EVPs sold shares on Dec. 19 (3,351 at $342.10 and 1,677 at $345), and insiders sold 15,220 shares worth $5.28 million over the last three months, leaving insiders with 0.38% ownership.
• Analysts are cautiously bullish: the consensus rating is "Moderate Buy" (11 Buys, 2 Holds) with an average price target of $399, while recent firm targets cluster around $415–420.

Capital Research Global Investors boosted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 0.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,661,033 shares of the company's stock after buying an additional 15,714 shares during the period. Capital Research Global Investors owned about 1.37% of Cencora worth $831,653,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. IAG Wealth Partners LLC bought a new position in shares of Cencora in the third quarter worth about $30,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock worth $31,000 after purchasing an additional 43 shares in the last quarter. Cloud Capital Management LLC acquired a new position in Cencora in the third quarter valued at about $31,000. Caitlin John LLC acquired a new position in shares of Cencora in the 3rd quarter valued at approximately $31,000. Finally, Westside Investment Management Inc. increased its position in shares of Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company's stock worth $33,000 after acquiring an additional 70 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm's stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 15,220 shares of company stock worth $5,282,867 over the last three months. Insiders own 0.38% of the company's stock.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent research reports. Evercore lowered their price objective on shares of Cencora from $440.00 to $420.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Jefferies Financial Group upgraded Cencora from an "underperform" rating to a "buy" rating in a report on Thursday, January 22nd. Finally, Weiss Ratings upgraded Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research note on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $399.00.

Cencora Price Performance

Cencora stock opened at $351.97 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a market capitalization of $68.47 billion, a price-to-earnings ratio of 42.30, a PEG ratio of 1.69 and a beta of 0.68. The stock's 50 day moving average is $354.84 and its 200-day moving average is $337.51. Cencora, Inc. has a 12 month low of $251.94 and a 12 month high of $377.54.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. During the same quarter in the previous year, the business posted $3.73 earnings per share. Cencora's quarterly revenue was up 5.5% on a year-over-year basis. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora's dividend payout ratio is 28.85%.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.